Savara Financial Ratios
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.92+0.09 (+1.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Savara ratio analysis
Return on equity reached -58.5%, meaning Savara generated -0.59 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.15 versus 0.16 the year before, and the current ratio was 11.85. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Savara financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | — | — | — | — | — | 265.39 | — | — | — | — |
| Price / book | 6.17 | 3.63 | 5.53 | 2.20 | 1.15 | 1.06 | 1.60 | 2.34 | 2.18 | — |
| Operating margin | — | — | — | — | — | -19,182.9% | — | — | — | -2,737.0% |
| Net margin | — | — | — | — | — | -19,305.4% | — | — | — | -2,730.8% |
| Free cash flow margin | — | — | — | — | — | -15,518.7% | — | — | — | -2,094.5% |
| Return on equity (ROE) | -58.5% | -55.9% | -39.0% | -35.4% | -29.8% | -77.1% | -76.9% | -56.8% | -25.0% | — |
| Return on assets (ROA) | -46.9% | -45.0% | -30.8% | -27.3% | -24.4% | -50.8% | -57.4% | -40.4% | -18.7% | -37.8% |
| Debt / equity | 0.15 | 0.16 | 0.19 | 0.24 | 0.18 | 0.39 | — | — | — | — |
| Current ratio | 11.85 | 13.73 | 15.66 | 21.98 | 11.26 | 10.41 | 11.40 | 15.63 | 16.27 | 4.23 |
| Revenue growth | — | — | — | — | — | — | — | — | -100.0% | 640.7% |